Table 2.
Effects of Intensive Glucose Lowering on Cardiovascular Disease Events in Type 2 Diabetes
| Parameter | ACCORD (N = 10,251) | ADVANCE (N = 11,140) | VADT (N = 1,791) |
|---|---|---|---|
| Mean age | 62 | 66 | 60 |
| Duration of diabetes (years) | 10 | 8 | 11.5 |
| History of cardiovascular disease | 35% | 32% | 40% |
| Body mass index (kg/m2) | 32 | 28 | 31 |
| Baseline HbA1c | 8.3% | 7.5% | 9.4% |
| HbA1c achieved | 6.4% vs. 7.5% | 6.5% vs. 7.3% | 6.9% vs. 8.4% |
| Cardiovascular events, hazard ratio | 0.90 (P = 0.16) | 0.94 (P = 0.32) | 0.88 (P = 0.12) |
| Mortality, hazard ratio | 1.22 (P = 0.04) | 0.93 | 1.07 |
ACCORD, Action to Control Cardiovascular Risk in Diabetes; ADVANCE, Action in Diabetes and Vascular Disease—Preterax and Diamicron Modified Release Controlled Evaluation; VADT, Veterans Affairs Diabetes Trial; HbA1c, glycosylated hemoglobin.